Prasad Bollina Selected Research

Prostatic Neoplasms (Prostate Cancer)

1/2022	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
1/2020	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
1/2020	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
1/2020	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
1/2017	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
10/2016	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
1/2016	Couple-Based Psychosexual Support Following Prostate Cancer Surgery: Results of a Feasibility Pilot Randomized Control Trial.
11/2010	Endoscopic extraperitoneal radical prostatectomy: critical analysis of outcomes and learning curve.
1/2009	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial.
7/2004	Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Prasad Bollina Research Topics

Disease

11	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2003
6	Neoplasms (Cancer) 01/2022 - 05/2003
4	Neoplasm Metastasis (Metastasis) 01/2020 - 05/2003
3	Disease Progression 01/2020 - 10/2016
1	Urinary Incontinence 01/2020
1	Nocturia 01/2020
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 06/2004
1	Lymphatic Metastasis 05/2003

Drug/Important Bio-Agent (IBA)

4	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 10/2016
2	Hormones (Hormone)IBA 07/2004 - 05/2003
2	Messenger RNA (mRNA)IBA 06/2004 - 05/2003
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	3-hydroxy-5-estrane-17-carbonitrile (ACN)IBA 01/2017
1	2-(acetyloxy)benzoic acid 6-(nitrooxymethyl)-2-phenylmethyl ester (NO-ibuprofen)IBA 07/2004
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2004
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 07/2004
1	N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA 07/2004
1	Caspase 3 (Caspase-3)IBA 07/2004
1	ParaffinIBA 05/2003
1	AndrogensIBA 05/2003
1	Testosterone (Sustanon)FDA Link 05/2003
1	IsoenzymesIBA 05/2003
1	Dihydrotestosterone (Androstanolone)IBA 05/2003

Therapy/Procedure

4	Radiotherapy 01/2020 - 10/2016
3	Prostatectomy (Retropubic Prostatectomy) 01/2020 - 10/2016
1	Therapeutics 01/2016
1	Minimally Invasive Surgical Procedures 11/2010
1	Conformal Radiotherapy 01/2009
1	Chemoprevention 07/2004